Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.
Journal article
Rao VN. et al, (2024), Am Heart J, 271, 123 - 135
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Journal article
Cardoso P. et al, (2024), Diabetologia
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2023), J Diabetes
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Timing of SGLT2i initiation after acute myocardial infarction.
Journal article
von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Journal article
Taylor R. et al, (2023), Clin Sci (Lond)
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Journal article
Regan JA. et al, (2023), JCI Insight
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Journal article
Maddaloni E. et al, (2023), Diabetes Metab Res Rev
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2023), Diabetes Obes Metab
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Journal article
Maddaloni E. et al, (2023), Diabetes, Obesity and Metabolism
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Journal article
Green JB. et al, (2023), Diabetes, Obesity and Metabolism
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Journal article
Shields BM. et al, (2022), Nat Med
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Journal article
Shields BM. et al, (2022), Nat Med
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.
Journal article
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Journal article
Dennis JM. et al, (2022), Lancet Digit Health, 4, e873 - e883
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.
Journal article
Regan JA. et al, (2022), Sci Rep, 12